(Q40754620)

23 September 2017

title

Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma (English)

1 reference

23 September 2017

Trivedi C

1

1 reference

23 September 2017

Redman B

2

1 reference

23 September 2017

Flaherty LE

3

1 reference

23 September 2017

Kucuk O

4

1 reference

23 September 2017

Du W

5

1 reference

23 September 2017

Heilbrun LK

6

1 reference

23 September 2017

Hussain M

7

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

23 September 2017

1 reference

23 September 2017

volume

89

1 reference

23 September 2017

issue

2

1 reference

23 September 2017

page(s)

431-436

1 reference

23 September 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Oral etoposide in the treatment of hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Taxol: a novel investigational antimicrotubule agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Phase I trial of weekly paclitaxel in advanced lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

One-sample multiple testing procedure for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000715%2989%3A2%3C431%3A%3AAID-CNCR31%3E3.0.CO%3B2-B

10.1002/1097-0142(20000715)89:2<431::AID-CNCR31>3.0.CO;2-B

21 January 2018

Identifiers

DOI

1 reference

23 September 2017

1 reference